Resident Blog - Edith Ford

from The mTOR You Know · host The mTOR You Know

PGY2 SOT Edith Ford joins us from Mayo Clinic in Phoenix, Arizona to discuss "A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection", which has recently received Breakthrough Therapy Designation for ABMR in kidney transplant recipients, as well as a quick discussion on antibody-mediated rejection and CD38 inhibitors.

Episode metadata supplied by the publisher feed · Published Nov 26, 2024

Embed this episode

Attribution link and audio player

NOW PLAYING

Resident Blog - Edith Ford

0:00 20:57

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The mTOR You Know?

This episode is 20 minutes long.

When was this The mTOR You Know episode published?

This episode was published on November 26, 2024.

Can I download this The mTOR You Know episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!